Nexthera Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Nexthera Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-500,000	Closed	-$10.4M	–	25
2018 Q3	$10.4M	Buy	+500,000	New	+$7.87M	1.99%	14

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital's ACAD Position: Q4 2018 in Review

Nexthera Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 43,980 shares — an estimated $913K sold.

Nexthera Capital first reported a position in ACAD in Q3 2018 and held it in 1 quarter. The position peaked at $913K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

Nexthera Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 43,980 Acadia Pharmaceuticals shares in Q4 2018, an estimated $913K.
Nexthera Capital first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Nexthera Capital's Acadia Pharmaceuticals position peaked at $913K in Q3 2018.
186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.